Booming New Drug Sector Can’t Hide Weakness in Medical Devices: Slowing Medical Device Growth Drags Down Johnson & Johnson (JNJ.US) Q2 Strong Earnings
智通财经2026/07/16 13:06Zhitong Finance APP reports that, thanks to the strong growth in drugs for treating cancer, inflammatory diseases, and treatment-resistant depression, Johnson & Johnson (JNJ.US) exceeded expectations in its second-quarter sales. The financial report shows that Johnson & Johnson's Q2 revenue reached $25.31 billion, an increase of 6.6% year-on-year, surpassing expectations by $250 million; non-GAAP earnings per share were $2.90, $0.05 above expectations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Finance Minister Reiterates Concerns: Yen Undervaluation is a "Big Problem," Will Cooperate Closely with the US to Maintain Forex Market Stability
Japanese Finance Minister Masato KATAYAMA stated that the weakness of the yen remains an ongoing concern. Japan and the United States will continue to maintain close contact in order to seek orderly functioning of the foreign exchange market.
Gold bounces off eight-week low; not out of the woods amid rising Fed hike bets
The "Endgame" of De-globalization: A Historic Battle for Metals!
Consulting giant Bain sounds the alarm: The global AI industry needs to achieve $6 trillion in annual revenue to sustain the “cash burn” of data centers
Bain stated that by 2031, the global artificial intelligence (AI) industry needs to achieve annual revenue of $6 trillion in order to justify the massive capital investment currently being made in building data centers worldwide.
Crypto prices
More
